Sign up online today & collaborate
or click here to find out more
The US Food and Drug Administration has approved Novartis’ once-daily pill Odomzo for locally advanced basal cell carcinoma that has returned following surgery or radiation therapy, or for patients unable to have these interventions.
BCC consists of abnormal, uncontrolled growths or lesions that arise in the skin's basal cells, which line the deepest layer of the epidermis, and accounts for more than 80% of non-melanoma skin cancers.
For more click here